DOCSLIB.ORG

Pharmacological Treatment for Buerger's Disease (Review)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacological Treatment for Buerger's Disease (Review) Cochrane Database of Systematic Reviews Pharmacological treatment for Buerger’s disease (Review) Cacione DG, Macedo CR, Baptista-Silva JCC Cacione DG, Macedo CR, Baptista-Silva JCC. Pharmacological treatment for Buerger’s disease. Cochrane Database of Systematic Reviews 2016, Issue 3. Art. No.: CD011033. DOI: 10.1002/14651858.CD011033.pub3. www.cochranelibrary.com Pharmacological treatment for Buerger’s disease (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 7 OBJECTIVES ..................................... 8 METHODS ...................................... 8 RESULTS....................................... 10 Figure1. ..................................... 11 Figure2. ..................................... 12 Figure3. ..................................... 13 Figure4. ..................................... 16 ADDITIONALSUMMARYOFFINDINGS . 17 DISCUSSION ..................................... 24 AUTHORS’CONCLUSIONS . 25 ACKNOWLEDGEMENTS . 25 REFERENCES ..................................... 26 CHARACTERISTICSOFSTUDIES . 28 DATAANDANALYSES. 37 Analysis 1.1. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 1 Ulcer healing (8 weeks) - iloprost200mcg. ................................ 38 Analysis 1.2. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 2 Ulcer healing (8 weeks) - iloprost400mcg. ................................ 39 Analysis 1.3. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 3 Ulcer healing (6 months) - iloprost200mcg. ................................ 39 Analysis 1.4. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 4 Ulcer healing (6 months) - iloprost400mcg. ................................ 40 Analysis 1.5. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 5 Complete relief of rest pain (8 weeks)-iloprost200mcg. 40 Analysis 1.6. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 6 Complete relief of rest pain (8 weeks)-iloprost400mcg. 41 Analysis 1.7. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 7 Complete relief of rest pain (6 months)-iloprost200mcg.. 41 Analysis 1.8. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 8 Complete relief of rest pain (6 months)-iloprost400mcg.. 42 Analysis 1.9. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 9 Rate of amputation - iloprost 200mcg. ................................... 42 Analysis 1.10. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 10 Rate of amputation - iloprost400mcg. ................................ 43 Analysis 2.1. Comparison 2 Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 1 Ulcer healing (4 weeks)..................................... 43 Analysis 2.2. Comparison 2 Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 2 Ulcer healing (6 months). ................................... 44 Analysis 2.3. Comparison 2 Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 3 Complete relief of restpain(4weeks)................................. 44 Analysis 2.4. Comparison 2 Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 4 Rate of amputation. .................................. 45 Analysis 3.1. Comparison 3 Prostacyclin versus prostaglandinE1,Outcome1Ulcerhealing. 45 Analysis 3.2. Comparison 3 Prostacyclin versus prostaglandin E1, Outcome 2 Complete relief of pain. 46 Analysis 4.1. Comparison 4 Folic acid versus placebo, Outcome 1 Pain (0 month). 46 Analysis 4.2. Comparison 4 Folic acid versus placebo, Outcome 2 Pain (2 months). 47 Pharmacological treatment for Buerger’s disease (Review) i Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Analysis 4.3. Comparison 4 Folic acid versus placebo, Outcome 3 Pain (6 months). 47 Analysis 4.4. Comparison 4 Folic acid versus placebo, Outcome 4 Change in rate of amputation (2 months). 48 Analysis 4.5. Comparison 4 Folic acid versus placebo, Outcome 5 Change in rate of amputation (6 months). 48 APPENDICES ..................................... 48 FEEDBACK...................................... 51 WHAT’SNEW..................................... 52 CONTRIBUTIONSOFAUTHORS . 53 DECLARATIONSOFINTEREST . 53 SOURCESOFSUPPORT . 53 DIFFERENCES BETWEEN PROTOCOL AND REVIEW . .... 54 INDEXTERMS .................................... 54 Pharmacological treatment for Buerger’s disease (Review) ii Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Pharmacological treatment for Buerger’s disease Daniel G Cacione1, Cristiane R Macedo2, Jose CC Baptista-Silva3 1Department of Surgery, UNIFESP - Escola Paulista de Medicina, São Paulo, Brazil. 2Brazilian Cochrane Centre, Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde, São Paulo, Brazil. 3Evidence Based Medicine, Cochrane Brazil, Universidade Federal de São Paulo, São Paulo, Brazil Contact address: Daniel G Cacione, Department of Surgery, UNIFESP - Escola Paulista de Medicina, Rua Borges Lagoa, 564 cj 124, Vila Clementino, São Paulo, 04038000, Brazil. [email protected]. [email protected]. Editorial group: Cochrane Vascular Group. Publication status and date: Edited (no change to conclusions), comment added to review, published in Issue 3, 2016. Review content assessed as up-to-date: 13 April 2015. Citation: Cacione DG, Macedo CR, Baptista-Silva JCC. Pharmacological treatment for Buerger’s disease. Cochrane Database of Systematic Reviews 2016, Issue 3. Art. No.: CD011033. DOI: 10.1002/14651858.CD011033.pub3. Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ABSTRACT Background Buerger’s disease (thromboangiitis obliterans) is a non-atherosclerotic, segmental inflammatory pathology that most commonly affects the small and medium sized arteries, veins, and nerves in the upper and lower extremities. The etiology is unknown, but involves hereditary susceptibility, tobacco exposure, immune and coagulation responses. In many cases, there is no possibility of revascularization to improve the condition. Pharmacological treatment is an option for patients with severe complications, such as ischaemic ulcers or rest pain. Objectives To assess the effectiveness of any pharmacological agent (intravenous or oral) compared with placebo or any other pharmacological agent in patients with Buerger’s disease. Search methods The Cochrane Vascular Trials Search Co-ordinator searched their Specialised Register (last searched in April 2015) and the Cochrane Register of Studies (Issue 3, 2015). The review authors searched trial registers and the European grey literature; screened reference lists of relevant studies, and contacted study authors and major pharmaceutical companies. Selection criteria Randomised controlled trials (RCTs) involving pharmacological agents used in the treatment of Buerger’s disease. Data collection and analysis Two review authors, independently assessed the studies, extracted data and performed data analysis. Main results Five randomised controlled trials (total 602 participants) compared prostacyclin analogue with placebo, aspirin, or a prostaglandin analogue, and folic acid with placebo. No studies assessed other pharmacological agents such as cilostazol, clopidogrel and pentoxifylline or compared oral versus intravenous prostanoid. Compared with aspirin, intravenous prostacyclin analogue iloprost improved ulcer healing (risk ratio (RR) 2.65; 95% confidence interval (CI) 1.15 to 6.11; 98 participants; one study; moderate quality evidence), and helped to eradicate rest pain after 28 days Pharmacological treatment for Buerger’s disease (Review) 1 Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. (RR 2.28; 95% CI 1.48 to 3.52; 133 participants; one study; moderate quality evidence), although amputation rates were similar six months after treatment (RR 0.32; 95% CI 0.09 to 1.15; 95 participants; one study; moderate quality evidence). When comparing prostacyclin (iloprost and clinprost) with prostaglandin (alprostadil) analogues, ulcer healing was similar (RR 1.13; 95% CI 0.76 to 1.69; 89 participants; two studies; I² = 0%; very low quality evidence), as was the eradication of rest pain after 28 days (RR 1.57; 95% CI 0.72 to 3.44; 38 participants; one study; low quality evidence), while amputation rates were not measured. Compared with placebo, the effects of oral prostacyclin analogue iloprost were similar for: healing ischaemic ulcers (iloprost 200 mcg: RR 1.11; 95% CI 0.54 to 2.29; 133 participants; one study; moderate quality evidence, and iloprost 400 mcg: RR 0.90; 95% CI 0.42 to 1.93; 135 participants; one study; moderate quality evidence), eradication of rest pain after eight weeks (iloprost 200 mcg: RR 1.14; 95% CI 0.79 to 1.63; 207 participants; one study; moderate quality evidence, and iloprost 400 mcg: RR 1.11; 95% CI 0.77 to 1.59; 201 participants; one study; moderate quality evidence), and amputation rates after six months (iloprost 200 mcg: RR 0.54; 95% CI 0.19 to 1.56; 209 participants; one study, and iloprost 400 mcg: RR 0.42; 95% CI 0.13 to 1.31; 213 participants; one study). When comparing folic
Load more

Recommended publications
  • Xử Trí Quá Liều Thuốc Chống Đông
    XỬ TRÍ QUÁ LIỀU THUỐC CHỐNG ĐÔNG TS. Trần thị Kiều My Bộ môn Huyết học Đại học Y Hà nội Khoa Huyết học Bệnh viện Bạch mai TS. Trần thị Kiều My Coagulation cascade TIÊU SỢI HUYẾT THUỐC CHỐNG ĐÔNG VÀ CHỐNG HUYẾT KHỐI • Thuốc chống ngưng tập tiểu cầu • Thuốc chống các yếu tố đông máu huyết tương • Thuốc tiêu sợi huyết và huyết khối Thuốc chống ngưng tập tiểu cầu Đường sử Xét nghiệm theo dõi dụng Nhóm thuốc ức chế Glycoprotein IIb/IIIa: TM VerifyNow Abciximab, ROTEM Tirofiban SLTC, Hb, Hct, APTT, Clotting time Eptifibatide, ACT, aPTT, TT, and PT Nhóm ức chế receptor ADP /P2Y12 Uống NTTC, phân tích chức +thienopyridines năng TC bằng PFA, Clopidogrel ROTEM Prasugrel VerifyNow Ticlopidine +nucleotide/nucleoside analogs Cangrelor Elinogrel, TM Ticagrelor TM+uống ƯC ADP Uống Nhóm Prostaglandin analogue (PGI2): Uống NTTC, phân tích chức Beraprost, năng TC bằng PFA, ROTEM Iloprost (Illomedin), Xịt hoặc truyền VerifyNow TM Prostacyclin,Treprostinil Nhóm ức chế COX: Uống NTTC, phân tích Acetylsalicylicacid/Aspirin#Aloxiprin,Carbasalate, chức năng TC bằng calcium, Indobufen, Triflusal PFA, ROTEM VerifyNow Nhóm ức chế Thromboxane: Uống NTTC, phân tích chức +thromboxane synthase inhibitors năng TC bằng PFA, Dipyridamole (+Aspirin), Picotamide ROTEM +receptor antagonist : Terutroban† VerifyNow Nhóm ức chế Phosphodiesterase: Uống NTTC, phân tích chức Cilostazol, Dipyridamole, Triflusal năng TC bằng PFA, ROTEM VerifyNow Nhóm khác: Uống NTTC, phân tích chức Cloricromen, Ditazole, Vorapaxar năng TC bằng PFA, ROTEM VerifyNow Dược động học một số thuốc
    [Show full text]
  • Effect of Garlic in Comparison with Misoprostol and Omeprazole on Aspirin Induced Peptic Ulcer in Male Albino Rats
    Available online at www.derpharmachemica.com ISSN 0975-413X Der Pharma Chemica, 2017, 9(6):68-74 CODEN (USA): PCHHAX (http://www.derpharmachemica.com/archive.html) Effect of Garlic in Comparison with Misoprostol and Omeprazole on Aspirin Induced Peptic Ulcer in Male Albino Rats Ghada E Elgarawany¹, Fatma E Ahmed², Safaa I Tayel³, Shimaa E Soliman³ 1Departments of Physiology, Faculty of Medicine, Menoufia University, Egypt 2Pharmacology, Faculty of Medicine, Menoufia University, Egypt 3Medical Biochemistry, Faculty of Medicine, Menoufia University, Egypt ABSTRACT Aiming to evaluate the protective effect of garlic on aspirin induced peptic ulcer in comparison with misoprostol and omeprazole drugs and its possible mechanisms. Forty white male albino rats were used. Total acid content, ulcer area/mm2, histological study, mucosal & serum Total Antioxidant Capacity (TAC) by calorimetry and mucosal & serum PGE2 and serum TNF-α by ELISA were assayed. Titrable acidity and total acid output decreased in garlic, misoprostol and omeprazole treated groups. Garlic, misoprostol and omeprazole improved gastric mucosa and 2 decreased ulcer formation and ulcer area/mm . Aspirin decreased PGE2 in gastric mucosa and serum. Co-administration of garlic to aspirin significantly increased PGE2 near to normal in gastric mucosa. Aspirin significantly increased serum TNF-α than control and other groups. Garlic is suggested to protect the stomach against ulcer formation induced by aspirin by reducing gastric acidity, ulcer area, improve gastric mucosa, increasing PGE2 and decreasing TNF-α. Keywords: Aspirin, Garlic, Misoprostol, Omeprazole, Peptic ulcer INTRODUCTION Peptic ulcer is a worldwide problem, that present in around 4% of the population [1]. About 10% of people develop a peptic ulcer in their life [2].
    [Show full text]
  • Effects of Beraprost Sodium on Renal Function and Inflammatory Factors of Rats with Diabetic Nephropathy
    Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy J. Guan1,2, L. Long1, Y.-Q. Chen1, Y. Yin1, L. Li1, C.-X. Zhang1, L. Deng1 and L.-H. Tian1 1Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China 2Nursing School of North Sichuan Medical College, Nanchong, Sichuan, China Corresponding author: J. Guan E-mail: [email protected] / [email protected] Genet. Mol. Res. 13 (2): 4154-4158 (2014) Received November 19, 2012 Accepted November 13, 2013 Published June 9, 2014 DOI http://dx.doi.org/10.4238/2014.June.9.1 ABSTRACT. Beraprost sodium (BPS) is a prostaglandin analogue. We investigated its effects on rats with diabetic nephropathy. There were 20 rats each in the normal control group (NC), the diabetic nephropathy group (DN), and the BPS treatment group. The rats in DN and BPS groups were given a high-fat diet combined with low-dose streptozotocin intraperitoneal injections. The rats in the BPS group were given daily 0.6 mg/kg intraperitoneal injections of this drug. After 8 weeks, blood glucose, 24-h UAlb, Cr, BUN, hs-CRP, and IL-6 levels increased significantly in the DN group compared with the NC group; however, the body mass was significantly reduced in the DN group compared with the NC group. Blood glucose, urine output, 24-h UAlb, Cr, hs-CRP, and IL-6 levels were significantly lower in the BPS group than in the DN group; the body mass was significantly greater in the DN group. Therefore, we concluded that BPS can improve renal function and protect the kidneys of DN rats by reducing oxidative stress and generation of inflammatory cytokines; it also decreases urinary protein Genetics and Molecular Research 13 (2): 4154-4158 (2014) ©FUNPEC-RP www.funpecrp.com.br Beraprost sodium and diabetic nephropathy 4155 excretion of rats with diabetic nephropathy.
    [Show full text]
  • Dynamic Expression of Mrnas and Proteins for Matrix Metalloproteinases and Their Tissue Inhibitors in the Primate Corpus Luteum During the Menstrual Cycle
    Molecular Human Reproduction Vol.8, No.9 pp. 833–840, 2002 Dynamic expression of mRNAs and proteins for matrix metalloproteinases and their tissue inhibitors in the primate corpus luteum during the menstrual cycle K.A.Young1,3, J.D.Hennebold1 and R.L.Stouffer1,2 1Division of Reproductive Sciences, Oregon National Primate Research Center, Oregon Health and Science University, 505 NW 185th Ave, Beaverton, Oregon 97006 and 2Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, OR 97201, USA 3To whom correspondence should be addressed. E-mail: [email protected] Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) may be involved in tissue remodelling in the primate corpus luteum (CL). MMP/TIMP mRNA and protein patterns were examined using real-time PCR and immunohistochemistry in the early, mid-, mid-late, late and very late CL of rhesus monkeys. MMP-1 (interstitial collagenase) mRNA expression peaked (by >7-fold) in the early CL. MMP-9 (gelatinase B) mRNA expression was low in the early CL, but increased 41-fold by the very late stage. MMP-2 (gelatinase A) mRNA expression tended to increase in late CL. TIMP-1 mRNA was highly expressed in the CL, until declining 21-fold by the very late stage. TIMP-2 mRNA expression was high through the mid-luteal phase. MMP-1 protein was detected by immunocytochemistry in early steroidogenic cells. MMP-2 protein was prominent in late, but not early CL microvasculature. MMP-9 protein was noted in early CL and labelling increased in later stage steroidogenic cells. TIMP-1 and -2 proteins were detected in steroidogenic cells at all stages.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Study Protocol
    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Uveitis and Cystoid Macular Oedema Secondary to Topical Prostaglandin
    Review Br J Ophthalmol: first published as 10.1136/bjophthalmol-2019-315280 on 12 June 2020. Downloaded from Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open angle glaucoma Jason Hu,1 James Thinh Vu ,1 Brian Hong,1 Chloe Gottlieb1,2,3 ► Additional material is ABSTRact complications and PGAs became popular due to published online only. To view, Background Of the side effects of prostaglandin having once- daily administration and few side please visit the journal online (http:// dx. doi. org/ 10. 1136/ analogues (PGAs), uveitis and cystoid macular oedema effects. PGAs have emerged as the most potent bjophthalmol- 2019- 315280). (CME) have significant potential for vision loss based IOP- lowering topical medication with bimatoprost on postmarket reports. Caution has been advised due reported as the most effective and unoprostone as 1 University of Ottawa, Faculty to concerns of macular oedema and uveitis. In this the least effective.3 of Medicine, Ottawa, Ontario, report, we researched and summarised the original data Canada The specific mechanism of action of PGAs is 2University of Ottawa Eye suggesting these effects and determined their incidence. not completely understood. It is known that they Institute, Ottawa, Ontario, Methods Preferred Reporting Items for Systematic increase uveoscleral outflow and there is growing Canada review and Meta- Analyses guidelines were followed. 3 evidence that they also increase conventional Ottawa Hospital Research Studies evaluating topical PGAs in patients with ocular 4 Institute, Ottawa, Ontario, outflow through Schlemm’s canal. The proposed Canada hypertension or open angle glaucoma were included. mechanism is that PGAs bind to E- type prostanoid MEDLINE, PubMed, EMBASE, CINAHL, Web of Science, receptors and prostaglandin F receptors in ‘the Cochrane Library, LILACS and ClinicalTrials.
    [Show full text]
  • 3720-3726-Domiciliary Treatment with Intravenous Iloprost
    European Review for Medical and Pharmacological Sciences 2016; 20: 3720-3726 Efficacy, safety and feasibility of intravenous iloprost in the domiciliary treatment of patients with ischemic disease of the lower limbs R. POLIGNANO1, C. BAGGIORE1, F. FALCIANI2, U. RESTELLI3, N. TROISI4, S. MICHELAGNOLI4, G. PANIGADA5, S. TATINI1, A. FARINA6, G. LANDINI1 1Medical Department, USL Centro Toscana, Florence, Italy 2Skin Lesions Observatory, USL Centro Toscana, Florence, Italy 3School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Centre for Research on Health Economics, Social and Health Care Management, Carlo Cattaneo University – LIUC, Castellanza (Varese), Italy 4Department of Surgery, Vascular and Endovascular Surgery Unit, San Giovanni di Dio Hospital, Florence, Italy 5Internal Medicine Unit, Santi Cosma e Damiano Hospital, Pescia, Italy 6Medical Affairs Department, Italfarmaco S.p.A., Cinisello Balsamo, Milan, Italy Abstract. – OBJECTIVE: Intravenous iloprost Introduction is an important option in the treatment of isch- emic disease of the lower limbs; however, the administration of therapy is frequently compro- The term ischemic disease of the lower limbs mised because of the need for long cycles of in- defines a wide number of pathological conditions fusion in a hospital setting. The aim of the study of both large and small peripheral arteries and is to evaluate the efficacy, safety, feasibility, and veins, including peripheral artery disease (PAD), the economic impact of infusion therapy in the diabetic microangiopathy, thromboangiitis oblite- outpatient setting. PATIENTS AND METHODS: rans or Buerger’s disease, and other inflammatory Twenty-four con- 1 secutive patients were treated with iloprost at vasculitis . Although these conditions are cha- their homes where they were administered a slow racterized by different pathogenetic mechanisms, rate of infusion for 24 hours a day, during 9.9 ± 2.3 similar clinical manifestations may occur due to days, with a portable syringe pump (Infonde®).
    [Show full text]
  • CHAPTER 1 General Introduction
    CHAPTER 1 General Introduction Chapter 1 1.1 General Introduction Drugs are defined as chemical substances that are used to prevent or cure diseases in humans and animals. Drugs can also act as poisons if taken in excess. For example paracetamol overdose causes coma and death. Apart from the curative effect of drugs, most of them have several unwanted biological effects known as side effects. Aspirin which is commonly used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever and as an anti-inflammatory medication, may also cause gastric irritation and bleeding. Also many drugs, such as antibiotics, when over used develop resistance to the patients, microorganisms and virus which are intended to control by drug. Resistance occurs when a drug is no longer effective in controlling a medical condition.1 Thus, new drugs are constantly required to surmount drug resistance, for the improvement in the treatment of existing diseases, the treatment of newly identified disease, minimise the adverse side effects of existing drugs etc. Drugs are classified in number of different ways depending upon their mode of action such as antithrombotic drugs, analgesic, antianxiety, diuretics, antidepressant and antibiotics etc.2 Antithrombotic drugs are one of the most important classes of drugs which can be shortly defined as ―drugs that reduce the formation of blood clots‖. The blood coagulation, also known as haemostasis is a physiological process in which body prevents blood loss by forming stable clot at the site of injury. Clot formation is a coordinated interplay of two fundamental processes, aggregation of platelets and formation of fibrin.
    [Show full text]
  • Topical Prostaglandin Analogues with and Without Preservatives on Tear Film Stability in the Long-Term Treatment of Glaucoma
    Jebmh.com Original Research Article Topical Prostaglandin Analogues with and without Preservatives on Tear Film Stability in the Long-Term Treatment of Glaucoma Humayoun Ashraf1, Shamim Ahmad2, Rupankar Sarkar3, Syed Wajahat Ali Rizvi4 1Professor, Institute of Ophthalmology, Jawaharlal Nehru Medical College, Faculty of Medicine, Aligarh Muslim University, Aligarh, Uttar Pradesh, India. 2Professor, Officer In-charge, Microbiology Section, Institute of Ophthalmology, Jawaharlal Nehru Medical College, Faculty of Medicine, Aligarh Muslim University, Aligarh, Uttar Pradesh, India. 3Resident, Institute of Ophthalmology, Jawaharlal Nehru Medical College, Faculty of Medicine, Aligarh Muslim University, Aligarh, Uttar Pradesh, India. 4Assistant Professor, Institute of Ophthalmology, Jawaharlal Nehru Medical College, Faculty of Medicine, Aligarh Muslim University, Aligarh, Uttar Pradesh, India. ABSTRACT BACKGROUND Prostaglandin analogues (PGAs) have proven to be the most potent of the anti- Corresponding Author: glaucoma medications in decreasing IOP, with little systemic side effects and Dr. Rupankar Sarkar, Institute of Ophthalmology, hence are the initial treatment of choice. Many PGAs contain preservatives which Jawaharlal Nehru Medical College, are associated with increased ocular side effects, the most common preservative Faculty of Medicine, Aligarh Muslim being benzalkonium chloride (BAK). BAK is known to cause cell toxicity and cell University (AMU), Aligarh – 202001, death in ocular surface tissues in a dose-dependent and time-dependent manner Uttar Pradesh, India. E-mail: [email protected] and often gives rise to ocular surface diseases, with the consequence of dysfunctional tear film in patients who are on long-term PGA therapy. We wanted DOI: 10.18410/jebmh/2020/178 to evaluate the long-term effects of prostaglandin analogue eye drops with and without preservative on tear film stability in glaucoma patients who are instilling Financial or Other Competing Interests: these medications on a long-term basis.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,683,038 B2 Thuren Et Al
    USOO9683 038B2 (12) United States Patent (10) Patent No.: US 9,683,038 B2 Thuren et al. (45) Date of Patent: Jun. 20, 2017 (54) METHODS OF REDUCING THE RISK OF FOREIGN PATENT DOCUMENTS EXPERIENCING A CARDIOVASCULAR (CV) EVENT OR A CEREBROVASCULAREVENT WO O216436 A2 2, 2002 NAPATIENT THAT HAS SUFFERED A WO 2010 136939 12/2010 QUALIFYING CV EVENT OTHER PUBLICATIONS (71) Applicants: Tom Thuren, Succasunna, NJ (US); Portolano et al., J. Immunol. (1993), vol. 150(3):880-887.* Andrew Zalewski, Elkins Park, PA Clackson et al., Nature, (1991), vol. 352: 624–628.* (US); Michael Shetzline, Randolph, NJ Ridker et al., “Interleukin-1 inhibition and the prevention of recur (US) rent cardiovascular events: Rationale and Design of the Canakinumab Ant-inflammatory Thrombosis Outcomes Study (72) Inventors: Tom Thuren, Succasunna, NJ (US); (CANTOS)”, American Heart Journal, Mosby Year Book Inc. US, vol. 162, No. 4, pp. 597-605, Sep. 14, 2011. Andrew Zalewski, Elkins Park, PA Ridker et al., “High-sensitivity C-reactive protein, vascular imag (US); Michael Shetzline, Randolph, NJ ing, and vulnerable plaque: more evidence to Support trials of anti (US) inflammatory therapy for cardiovascular risk reduction'. Circula tion Cardiovasuclar Imaging vol. 4. No. 3, pp. 195-197, May 2011. (73) Assignee: Novartis AG, Basel (CH) Rieke et al., “The human anti-IL limonoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of (*) Notice: Subject to any disclaimer, the term of this concept study in patients with rheumatoid arthritis'. Arthritis patent is extended or adjusted under 35 Research and Therapy, Biomed Central, London.
    [Show full text]